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ORIGINAL INVESTIGATION
Sodium glucose transporter 2 (SGLT2) 
inhibition with empagliflozin improves cardiac 
diastolic function in a female rodent model 
of diabetes
Javad Habibi1,4†, Annayya R. Aroor1,4†, James R. Sowers1,3,4,5, Guanghong Jia1,4, Melvin R. Hayden1, 
Mona Garro1,4, Brady Barron1,4, Eric Mayoux7, R. Scott Rector4,6, Adam Whaley‑Connell1,2,4 
and Vincent G. DeMarco1,3,4* 
Abstract 
Obese and diabetic individuals are at increased risk for impairments in diastolic relaxation and heart failure with 
preserved ejection fraction. The impairments in diastolic relaxation are especially pronounced in obese and diabetic 
women and predict future cardiovascular disease (CVD) events in this population. Recent clinical data suggest sodium 
glucose transporter‑2 (SGLT2) inhibition reduces CVD events in diabetic individuals, but the mechanisms of this CVD 
protection are unknown. To determine whether targeting SGLT2 improves diastolic relaxation, we utilized empa‑
gliflozin (EMPA) in female db/db mice. Eleven week old female db/db mice were fed normal mouse chow, with or 
without EMPA, for 5 weeks. Blood pressure (BP), HbA1c and fasting glucose were significantly increased in untreated 
db/db mice (DbC) (P < 0.01). EMPA treatment (DbE) improved glycemic indices (P < 0.05), but not BP (P > 0.05). At 
baseline, DbC and DbE had already established impaired diastolic relaxation as indicated by impaired septal wall 
motion (>tissue Doppler derived E′/A′ ratio) and increased left ventricular (LV) filling pressure (<E/E′ ratio). Although 
these abnormalities persisted throughout the study period in DbC, diastolic function improved with EMPA treatment. 
In DbC, myocardial fibrosis was accompanied by increased expression of profibrotic/prohypertrophic proteins, serum/
glucocorticoid regulated kinase 1 (SGK1) and the epithelial sodium channel (ENaC), and the development of these 
abnormalities were reduced with EMPA. DbC exhibited eccentric LV hypertrophy that was slightly improved by EMPA, 
indicated by a reduction in cardiomyocyte cross sectional area. In summary, EMPA improved glycemic indices along 
with diastolic relaxation, as well as SGK1/ENaC profibrosis signaling and associated interstitial fibrosis, all of which 
occurred in the absence of any changes in BP.
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Background
The global epidemic of obesity is largely responsible for 
the increased incidence of type 2 diabetes mellitus and 
associated cardiovascular diseases (CVD). Affected 
individuals are likely to have one or more CVD compli-
cations, such as hypertension and cardiac diastolic dys-
function; indeed, diabetes is often considered a CVD 
equivalent. In this regard, young (premenopausal) obese 
and diabetic women are particularly vulnerable to CVD 
[1, 2]. Normally, young lean woman are at lower risk 
for development of CVD compared to men. However, 
this sex-related cardioprotection is lost in conditions of 
obesity or diabetes [3]. Diastolic dysfunction, which is 
defined by delayed diastolic relaxation [4], is associated 
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with insulin resistance, cardiac fibrosis, hypertrophy, and 
inflammation [5, 6]. Diastolic heart failure, a CVD risk 
factor usually associated with aging, has dramatically 
increased in incidence in association with the increases 
in obesity and diabetes. Therefore, developing new strat-
egies to improve both glycemia and CVD out comes in 
individuals afflicted with diabetes would be highly desir-
able, especially for women.
Diastolic dysfunction is typically associated with inter-
stitial fibrosis and left ventricular (LV) hypertrophy 
that promote LV stiffness and impaired relaxation. In 
this regard, serum and glucocorticoid regulated kinase 
1 (SGK1), which is highly expressed in the diabetic 
heart and is stimulated by excess circulating glucose, is 
emerging as a mediator of cardiac fibrosis/stiffening and 
impaired cardiac relaxation [7–10]. SGK1 stimulates a 
number of ion channels, including the epithelial sodium 
channel (ENaC), as well as transporters, transcription 
factors and enzymes [11]. Indeed, we recently reported 
that fibrosis and stiffening of the aorta of overweight 
female mice fed a high fat, high sugar diet for 4 months 
was associated with increased aortic expression of SGK1 
and ENaC [12].
In diabetes, hyperglycemia promotes a state of glu-
cotoxicity, inflammation and oxidative stress which 
are associated with hypertension and end organ injury, 
including injury to the heart. In this regard, pharmaco-
logic inhibitors of the renal sodium–glucose cotrans-
porter 2 (SGLT2) are emerging as a novel group of drugs 
that lower blood glucose and HbA1c levels and improve 
whole body insulin sensitivity in animals and humans 
with diabetes, largely by blocking renal proximal tubu-
lar reabsorption of glucose which increases urinary glu-
cose excretion (glycosuria) [13, 14]. The mild osmotic 
effects of SGLT2 inhibitor treatment can lead to modest 
reduction in blood pressure (BP), an effect, along with 
the improvement in glucose control and weight reduc-
tion that could reduce the risk of CVD. Indeed, a recent 
meta-analysis demonstrated favorable cardiovascular 
outcomes in diabetes patients treated with empagliflo-
zin (EMPA) [15]. Administration of SGLT2 inhibitors to 
animals or humans with diabetes may also reduce adi-
posity, oxidative stress and expression of advanced glyca-
tion end products (AGE) and receptors for AGE (RAGE) 
[16]. Herein, we tested whether SGLT2 inhibitor therapy 
would attenuate the development of the earliest mani-
festation of diabetic heart disease, diastolic dysfunction, 
in part, by reducing blood pressure (BP), cardiac oxida-
tive stress and pro-fibrotic factors. Diastolic dysfunction 
is especially pronounced in obese, insulin resistant and 
diabetic females [1, 2, 17–19]. Specifically, we hypoth-
esized that the SGLT2i, EMPA would blunt the devel-
opment/progression of diastolic dysfunction and the 
associated abnormalities in cardiac remodeling in insulin 
resistant female diabetic db/db mice (Leprdb/db). Previ-
ous reports demonstrate that female db/db mice develop 
diastolic dysfunction, cardiac fibrosis and left ventricular 
hypertrophy (LVH) [20–22]. The db/db model is clini-
cally relevant in that hyperleptinemia and leptin resist-
ance, obesity and associated heart disease are seen in the 
human obese population and leptin levels are elevated in 
conditions of chronic heart failure and chronic hyperten-
sion. The db/db mouse exhibits a non-dipping BP pat-
tern, diastolic dysfunction and cardiac remodeling; these 
CVD features of metabolic disease are also observed in 
obese and insulin resistant humans [20, 23–27]. Herein, 
we examined whether the anticipated improvement in 
diastolic function and cardiac remodeling with EMPA 
treatment would be associated with reductions in myo-
cardial interstitial fibrosis, profibrotic signaling proteins, 




All animal procedures were approved by the Harry S 
Truman Veterans Affairs Memorial Hospital Subcom-
mittee for Animal Safety (SAS) and the University of 
Missouri IACUC. Eight week old female db/db (BKS.Cg-
Dock7m+/+Leprdb/J) and wild-type control (C57BLKS/J) 
mice were purchased from Jackson Labs and were housed 
under standard laboratory conditions where room tem-
perature was 21–22  °C and light and dark cycles were 
12 h each. Three different cohorts of mice were used for 
these studies. Each cohort consisted of three groups of 
mice including lean untreated controls (CkC), untreated 
db/db (DbC) and db/db treated with EMPA (DbE) for 
5 weeks. In total there were 17 CkC, 19 DbC and 19 DbE. 
The first and second cohorts consisted of 5–6 mice per 
group and subsets of these mice were used for cardiac 
function, urine and plasma biochemistry, histological 
(light and electron microscopy) and immunological stud-
ies. The third cohort consisted of 6–7 mice per group 
that were used primarily for ambulatory BP monitoring. 
Two DbC and two DbE were removed from Cohort3 fol-
lowing acute complications from telemetry implant sur-
gery. The radiotransmitter in another DbC failed in the 
middle of the study and one CkC with a radiotransmit-
ter succumbed late in the study. Of the 55 mice used, six 
mice, all from Cohort3, did not complete the study. The 
treatment period began when mice were 11 weeks of age 
and ended 5  weeks later when mice were 16  weeks of 
age. Previous reports indicate that cardiac dysfunction 
and remodeling in female db/db mice begin to develop 
and progress during the time frame of our experiment 
[20–22].
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EMPA administration
EMPA is a potent and competitive inhibitor of SGLT2 
with the highest selectivity profile of recently tested 
SGLT2i [28]. We mixed EMPA in normal mouse chow 
(Purina Diet 5008) at a concentration(60 mg kg−1 of diet) 
calculated to deliver 10  mg  kg−1  day−1 based on food 
intake [13]. This dose of EMPA significantly improves 
HbA1c, 2  h glucose concentration during oral glucose 
tolerance test (OGTT) and insulin sensitivity by insulin 
euglycemic-hyperinsulinemic clamp and tends to lower 
circulating lipids in 17 week old female db/db mice [13].
Blood and tissue biochemistry
Mice were fasted for 4 h in the morning (5–9 a.m.) prior 
to collection of a small blood sample from the tail vein. 
Blood was analyzed for glucose using an Alpha Trak II 
glucometer and for HbA1c using a DCA Vantage Ana-
lyzer (Seimens, Malvern, PA). Samples were drawn 
immediately prior to the start of the treatment period, 
midway and at the end of the study. At the end of the 
study mice were anesthetized with 3% isoflurane and a 
terminal blood sample was drawn immediately from the 
left ventricle. Blood was centrifuged and plasma was 
stored at −80  °C. Plasma was analyzed for insulin con-
centration using an ELISA kit specific for mouse insu-
lin using a previously established protocol [29], as well 
as cholesterol, triglycerides, alanine aminotransferase 
and uric acid using commercially-available automated 
assays (Beckman-Coulter, Inc., Brey, CA). Liver samples 
were analyzed for triglyceride content using a previously 
established protocol [30]. Plasma electrolytes (Na+, K+ 
and Cl−) were measured on the same clinical chemistry 
platform using ion-specific electrodes.
Urine analyses
Immediately prior to the start of treatment, in the mid-
dle of the treatment period and within 48  h of the end 
of treatment, mice were placed in metabolic chambers 
for 24  h urine collection and subsequent determination 
of concentrations of electrolytes and glucose. Urine was 
stored at −80 °C except for a 60 µl aliquot that was refrig-
erated overnight and analyzed for microalbumin and cre-
atine, as well as the ratio of micro-albumin to creatine 
as a standardized measure of microalbuminuria, using a 
DCA Vantage analyzer.
Body composition
Prior to both the start of treatment and the end of the 
study,whole body composition was analyzed by nuclear 
magnetic resonance spectroscopy (Echo MRI, Houston, 
TX).
BP monitoring
Ambulatory BP and BP dipping status during the light 
and dark cycles were monitored weekly by radiotelem-
etry as previously described [31, 32].
Echocardiography
Transthoracic echocardiography (TTE) was performed 
on isoflurane (1.75% in an oxygen stream) anesthetized 
mice as previously described [31, 33] using a GE Vividi 
ultrasound system. Initially, we performed TEE immedi-
ately prior to the beginning of the treatment period and 
again at the end of the treatment period.
Quantification of interstitial fibrosis
One mm thick coronal slices of the heart just below the 
level of the papillary muscle were fixed in paraform-
aldehyde, embedded in paraffin, sectioned at 5  μ and 
stained for collagens using picro-Sirius-red, as previously 
described [34]. Images were taken with 5× and 40× 
objective lenses. A region of interest rectangle of known 
area was randomly placed in three areas and images were 
captured using a Nikon50i microscope, a 40× objective 
and cool snapcf camera and software. Each image was 
auto-leveled with Photoshop and the intensity of pink 
color was normalized to area and quantified using Meta-
Vue software. For each animal an average estimate of 
fibrosis was calculated from the three determinations of 
collagen staining.
Heart immunohistochemistry and immunoblotting
To evaluate the level of oxidative/nitrosative damage to 
myocardial proteins samples of the left ventricle (LV) 
free wall were fixed, embedded in paraplast, sectioned 
and assessed for 3-nitrotyrosine (3-NTY) residue using 
an immunofluorescence technique we described pre-
viously [34, 35]. LV tissue sections were also evaluated 
by immunofluorescence for wheat germ agglutinin 
(WGA, 1:50, #W11261, Invitrogen), AGE (1:100, #23722, 
Abcam), RAGE (1:50, #AF1179, R&D), SGK1 (1:100, 
#32374, Abcam) and ENaC (1:200, #77385, Abcam) 
expression. Average grey scale intensity was quantified 
within fixed region of interest rectangles as previously 
described [35].
Preparation of LV homogenates, electrophoresis and 
immunoblotting were described previously [34]. The fol-
lowing antibodies were used: phospho-Akt Ser308 (1:1000; 
#4056, Cell Signaling Technology, Inc or CST), phospho-
Akt Ser473 (1:1000; #9271, CST), Akt (1:1000; #9272, CST), 
eNaC (1:1000; #77385, Abcam), RAGE (1:1000; #AF1179, 
R&D), Phospho-ERK T202/204 (1:1000; #9106, CST), ERK 
(1:1000; #4695, CST) and pan-actin (1:1000; #4968, CST).
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Ultrastructure analysis using transmission electron 
microscopy (TEM)
Briefly, samples of the LV free wall were cut into 2 mm 
squares and placed immediately in primary TEM fixative 
as previously described. Specimens were then placed in 
resin and polymerized at 60  °C for 24  h. Ultrathin sec-
tions (85  nm) were stained with 5% uranyl acetate and 
Sato’s Triple lead stain. A JOEL 1400-EX TEM (Joel, 
Tokyo, Japan) was used to view three fields randomly 
chosen per mouse to obtain three 2000× images per LV 
[36].
Statistical analysis
Results are reported as the mean  ±  SE. Differences in 
outcomes were determined using one-way ANOVA and 
Bonferroni post hoc tests for paired comparisons and 
were considered significant when P  <  0.05. For com-
parisons regarding plasma insulin concentration at the 
end of the study, a Kruskal–Wallis ANOVA was used in 
place of standard ANOVA. All statistical analyses were 
performed using Sigma Plot (version 12) software (Systat 
Software, Point Richmond, CA).
Results
Baseline parameters
Compared to CkC mice, body weights of DbC and DbE 
mice were both 2.74-fold greater and this was due largely 
to the more than 12-fold increases in whole body fat 
mass, and to a lesser extent to 20 and 24% increases in 
whole body lean mass, in DbC and DbE, respectively 
(Additional file  1: Figure S1A; Table  1; P  <  0.001). The 
slightly greater gain in lean mass in DbE compared to 
DbC did not reach statistical significance (Additional 
file 1: Figure S1B–E). The percentage of whole body water 
weight of DbC and DbE was less than half that of CkC 
and did not differ between the treated and untreated db/
db groups.
Metabolic parameters
Plasma cholesterol, triglycerides and alanine aminotrans-
ferase (ALT) were similarly elevated in both DbC and 
DbE indicating metabolic dyslipidemia and liver impair-
ment in DbC and DbE (Table 1). Compared to CkC, liver 
triglyceride content was elevated in DbC and this was not 
altered by EMPA (Table  1). Plasma electrolytes did not 
differ among groups (not shown).
Baseline fasting glucose and HbA1c of CkC mice were 
155 ± 15 mg dl−1 and 3.7 ± 0.1%, respectively and these 
parameters did not differ at the end of the study (Fig. 1a, 
b). At both measuring times, i.e., before treatment 
began and at the end of the treatment period, DbC and 
DbE mice had elevated fasting glucose and HbA1c con-
sistent with diabetes, compared to CkC. By the end of 
the 5 week study period, the fasting glucose and HbA1c 
of DbC were both elevated compared to pre-treatment 
levels. Compared to pre-treatment values, DbE exhib-
ited lower fasting glucose and HbA1c was unchanged. 
Moreover, both glycemic parameters in DbE were sig-
nificantly reduced by the end of the treatment period 
compared to DbC. These data indicate that progressing 
hyperglycemia was abrogated by EMPA. In this study, 
16  week old DbC and DbE had higher plasma insulin 
concentrations compared to CkC (P  <  0.05 for each) 
(Fig. 1c). The higher insulin levels in DbE were associ-
ated with an increase in pancreas weight compared to 
CkC and DbC (Fig. 1d). To evaluate urine glucose excre-
tion (UGE) at the end of the study, we normalized urine 
glucose concentration to fasting glucose concentra-
tion and observed that the UGE of DbC and DbE mice 
were 54- and 111-fold higher than that of CkC (Fig. 1e; 
P < 0.001).
BP and BP dipping status is unaffected by SGLT2i
At the end of the treatment period daytime ambulatory 
systolic BP (SBP) and diastolic BP (DBP) were elevated in 
both DbC and DbE, compared to CkC (Fig. 2a). SBP and 
DBP were also elevated during the dark cycle although 
the trends were not significant over as many time points 
Table 1 Baseline parameters, including  body and  liver 
weights, as  well as  post-treatment plasma metabolic 
markers of  lean control (CkC), untreated db/db (DbC) 
and db/db mice treated with EMPA (DbE)
Values are mean ± SE. Post-hoc comparisons; P < 0.05 for * CkC vs DbC; † DbCvs 
DbE; and § CkC vs DbE. Sample sizes are noted in parentheses
Parameter ANOVA CkC DbC DbE




0.001 18.9 ± 0.2 46.1* ± 0.7 45.4§ ± 0.7
 Post‑treatment 
body weight (g)
0.001 19.2 ± 0.3 53.6* ± 1.0 53.5§ ± 0.7
 Delta (g) 0.001 0.17 ± 0.29 7.50* ± 0.76 8.32§ ± 0.50
 % Increase in  
body weight
0.001 0.7 ± 1.6 13.8* ± 1.3 15.5§ ± 0.9
Hepatic
 Liver weight (mg) 0.001 835 ± 37 2460*,† ± 92 2031§ ± 72
 Triglycerides 
(nmol g−1)




0.001 76 ± 5 145* ± 3 148§ ± 6
 Triglycerides 
(mg dl−1)
0.001 126 ± 9 310* ± 18 301§ ± 20
 Alanine  
aminotransferase 
(U l−1)
0.001 27 ± 2 78* ± 5 69§ ± 8
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as occurred during the light cycle (Fig. 2b). The percent-
age decrease in SBP between the light and dark cycles, 
also known as BP dipping status, ranged between 7.5 
and 9.8% in CkC over study period (Fig. 2c). It should be 
noted that normal BP dipping is defined as a decrease 
in BP of at least 10% between the light and dark cycles. 
BP dipping status tended to be similarly impaired in 
DbC and DbE between 12 and 15 weeks of age, although 
all three groups of mice had similar dipping status at 
16 weeks of age.
Cardiac function is improved with SGLT2i
Pre‑treatment
Compared to CkC, DbC and DbE exhibited impairments 
in diastolic relaxation (Table  2), including reductions in 
early septal annular velocity (E′) and the ratio of early 
(E′) to late (A′) septal annular velocity. This occurred in 
association with an increase in an index of LV filling pres-
sure, the E/E′ ratio, specifically, the ratio of peak early 
mitral inflow velocity to peak early septal annular veloc-
ity. Left atrial (LA) diameter relative to the diameter of 
the aorta (Ao) increases in response to an increase in LV 
filling pressure. The observed increase in the ratio of LA 
to Ao diameters is consistent with increased LV filling 
pressure (E/E′ ratio) in both groups of the db/db mice. In 
contrast, we did not observe differences among groups in 
early (E) or late (A) mitral inflow velocity or in the E/A 
ratio, the latter being an often reported marker of dias-
tolic dysfunction. There were no significant differences 
in the systolic function parameters, ejection fraction (EF) 
and fractional shortening (FS) among the three groups. 
As expected in the setting of obesity, cardiac output (CO) 
and stroke volume (SV) were elevated in the DbC and 
DbE groups compared to the lean CkC mice. Measures 
of LV wall thickness tended to be slightly greater in DbC 
and DbE and LV lumen diameters were similar among 
groups. Relative wall thickness did not vary significantly 
among the three groups of mice.
End of treatment
The diastolic impairments observed in the untreated DbC 
group at the earlier time point were, in most cases, main-
tained until the end of the study (Table 2; Fig. 3). On the 
other hand, early septal annular velocity (E′) tended to 
increase and late septal annular velocity (A′) tended to 
decrease in DbE relative to measurements taken 5 weeks 
earlier. These modest improvements in E′ and A′ con-
tributed to the significant increase in the E′/A′ ratio in 










































































Fig. 1 Empagliflozin improves dysglycemia in db/db mice. Db/db mice have elevated fasting glucose and HbA1c levels prior to the start of treat‑
ment. During the 5 week study period, dysglycemia was sustained in untreated db/db mice (DbC); however both a fasting glucose and b HbA1c 
were reduced in db/db treated with empagliflozin (DbE) by the end of the study. At the end of the study, DbE had increased c serum insulin 
concentrations and d pancreas mass e compared to CKC and DbC. e Compared to CkC, urine glucose excretion (UGE) was elevated in both db/db 
groups of mice, but UGE was twofold higher in DbE compared to DbC. *P < 0.05 compared to CkC at the same time point; †P < 0.05 compared to 
DbC at the same time point
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DbE (Fig. 3a). Moreover, LV filling pressure (E/E′) was sig-
nificantly lower in DbE compared to DbC, yet this was not 
accompanied by a decrease in the LA/Ao ratio  (Fig. 3b). 
This suggests that reversal of LA remodeling may not 
occur contemporaneously with therapeutic reduction in 
filling pressure [37]. In contrast, we did not observe differ-
ences among groups in early (E) or late (A) mitral inflow 
velocity or in the E/A ratio, nor were there differences in 
indices EF or FS. Relative to CkC, CO and SV were still 
significantly elevated in the DbC, but not DbE mice.
LV hypertrophy is ameliorated by SGLT2i
We observed increases in LV mass, determined by 
M-mode ultrasound, in DbC and DbE compared to CkC 
(Table  2). On the other hand, echocardiographic meas-
ures of LV wall thickness at end diastole (LVAWTd and 
LVPWTd) and lumen diameters at end diastole and end 
systole (LVIDd and LVIDs) were similar among the three 
groups of mice. Left ventricular cardiomyocyte cross sec-
tional area, a correlate of cardiomyocyte hypertrophy, 
was elevated in both DbC compared to CkC (Fig.  4a). 
Interestingly, cardiomyocyte cross sectional area was sig-
nificantly reduced in DbE compared to DbC, although it 
did not reduce to that of CkC. The increases in CO, LV 
filling pressure, cardiomyocyte size and LV mass, in the 
absence of an increase in LV wall thickness, comprise 
a suite of traits suggestive of eccentric hypertrophy. It 
should be noted that the most prevalent LV remodeling 
abnormality in obese hypertensive individuals is eccentric 
hypertrophy [38]. The lower CO and LV filling pressure 
observed in DbE are consistent with reduced cardiomyo-
cyte cross sectional area and suggest that the progression 
of the hypertrophic phenotype is mildly ameliorated with 
EMPA treatment.
Myocardial fibrosis is improved with SGLT2i
At the end of treatment, the myocardium of DbC exhib-
ited 50% greater picrosirius red staining than that of 
CkC, indicative of increased collagen I and III deposi-
tion in the interstitium (Fig.  4b). Myocardial picrosirius 
red staining in DbE was significantly reduced compared 
to DbC and was not different from CkC. Immunostain-
ing for the more tensile type 1 collagen revealed a similar 
pattern of increasing collagen 1 in DbC compared to both 
CkC and DbE (14.8 ± 3.3 vs 11.1 ± 0.9 and 10.2 ± 0.3, 
respectively; P > 0.05), however the differences were not 
statistically different.
Myocardial oxidative/nitrosative stress, AGE and RAGE
Oxidant stress contributes to AGE/RAGE activation 
in diabetes. The myocardium of DbC exhibited 2.6-fold 
greater 3-NTY immunostaining compared to CkC, indic-
ative of increased accumulation of nitro tyrosinolated 
protein damage in the interstitium (Fig.  4c). Compared 
to DbC, staining of 3-NTY tended to be slightly lower 
in DbE, compared to DbC, but was not significant 
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Fig. 2 Mean ambulatory systolic and diastolic blood pressures were recorded at weekly intervals during the light a and dark b cycles. Compared to 
CkC, both DbC and DbE exhibited a mild elevation in blood pressure (P < 0.05), especially during the light cycle and tended to have impaired blood 
pressure dipping (c), neither of which was affected by empagliflozin treatment. *P < 0.05DbC vs CkC and §P < 0.05 DbE vs CkC
Page 7 of 15Habibi et al. Cardiovasc Diabetol  (2017) 16:9 
(P  >  0.05). In DbC, there were concomitant increases 
of 55 and 66%, respectively, in myocardial expression of 
AGE and RAGE, compared to CkC (Fig.  5a–c). In the 
myocardium of CkC, the basal level of AGE staining indi-
cates low level expression in the parenchyma with more 
prominent staining in the vascular wall. In the DbC, 
there are increases in AGE staining in both the paren-
chyma and vascular wall. EMPA did not reduce the accu-
mulations of AGE or RAGE in the DbE heart. Although 
oxidant damage likely contributes to fibrosis and diastolic 
dysfunction, we and others have observed interventional 
improvement in diastolic dysfunction in the absence of 
significant reductions in myocardial oxidative/nitrosative 
stress [31, 39]. 
SGK1 and ENaC expression are reduced with SGLT2i
SGK1 is highly expressed in the myocardium, especially 
in the setting of obesity and diabetes and is emerging as 
a contributor to cardiac fibrosis/stiffening, hypertro-
phy and impaired cardiac relaxation [7–9]. Additionally, 
Table 2 Summary (mean  ±  SE) of  cardiac pulse wave, tissue Doppler and  M-mode imaging parameters measured 
before (pre) and after treatment (post) with the SGLT-2 inhibitor
E velocity of early mitral flow, A velocity of late mitral flow, Dt deceleration time of early mitral inflow, E′ early peak velocity of septal annulus, A′ late peak velocity of 
septal annulus, E/E′ index of LA filling pressure, (E/E′)/LVIDd index of diastolic stiffness, IVRT isovolumic relaxation time, LA left atrium diameter, Ao aorta diameter, 
EF ejection fraction, FS fractional shortening, CO cardiac output, SV stroke volume, LVAWTd anterior wall thickness at end diastole, LVIDd LV inner diameter at end 
diastole, LVPWTd LV wall thickness at end diastole, LVIDs LV inner diameter at end systole, RWT relative wall thickness, LVM LV mass, TL tibia length (only available post-
treatment), ND no differences
Numbers in parentheses are sample sizes. Within time point post hoc comparisons: * P < 0.05 for CkC vs DbC; † DbC vs DbE; § CkC vs DbE; a P < 0.051CkC vs DbE
Parameter Pre-treatment Post-treatment
CkC (9) DbC (6) DbE (6) P value CkC (9) DbC (6) DbE (6) P value
Diastolic function
 E, m s−1 665 ± 28 641 ± 40 696 ± 50 ND 632 ± 25 680 ± 29 647 ± 57 ND
 A, m s−1 455 ± 34 508 ± 19 463 ± 34 ND 417 ± 24 510 ± 31 470 ± 45 ND
 E/A 1.52 ± 0.12 1.26 ± 0.05 1.53 ± 0.12 ND 1.5 ± 0.08 1.35 ± 0.09 1.39 ± 0.06 ND
 Dt, ms 29.4 ± 3.0 32.7 ± 3.9 27.8 ± 1.8 ND 24.9 ± 1.8 31.1 ± 3.3 26.3 ± 1.8 ND
 E′, m s−1 27.0 ± 1.8 14.0 ± 1.6* 15.9 ± 2.2 <0.001 26.9 ± 1.4 15.5 ± 1.7* 20.4 ± 1.2 <0.001
 A′, m s−1 21.5 ± 2.5 16.6 ± 0.8 18.0 ± 4.1 ND 19.0 ± 1.7 18.3 ± 2.7 11.9 ± 0.9§ 0.036
 E′/A′ 1.31 ± 0.09 0.84 ± 0.08* 0.93 ± 0.07§ 0.002 1.47 ± 0.11 0.89 ± 0.08*,† 1.76 ± 0.17 <0.001
 E/E′ 25.3 ± 1.7 48 ± 5.6* 47 ± 2.5§ <0.001 24 ± 1.6 46 ± 4.4*,† 29 ± 1.8 <0.001
 (E/E′/IDd) 8.7 ± 0.4 13.4 ± 1.8 12.4 ± 0.6 ND 7.8 ± 0.5 12.3 ± 1.3*,† 7.8 ± 0.9 0.009
 IVRT, ms 20.9 ± 1.8 19.9 ± 0.8 18.0 ± 1.0 ND 19.0 ± 2.3 16.0 ± 0.4 15.8 ± 0.4 ND
 LA, mm 1.55 ± 0.10 2.35 ± 0.13* 2.25 ± 0.10§ <0.001 1.40 ± 0.06 1.97 ± 0.03* 2.04 ± 0.1§ <0.001
 Ao, mm 1.21 ± 0.06 1.37 ± 0.02 1.42 ± 0.05 0.077 1.26 ± 0.06 1.29 ± 0.02 1.27 ± 0.05 ND
 LA/Ao 1.29 ± 0.07 1.72 ± 0.09* 1.60 ± 0.11a 0.009 1.14 ± 0.08 1.54 ± 0.11* 1.61 ± 0.1§ 0.003
Parameter Pre-treatment Post-treatment
CkC (5) DbC (6) DbE (6) P value CkC (5) DbC (6) DbE (6) P value
Systolic function
 EF, % 72 ± 6 76 ± 1 71 ± 2 ND 74 ± 2 74 ± 3 76 ± 2 ND
 FS, % 42 ± 5 44 ± 1 39 ± 2 ND 42 ± 2 43 ± 3 45 ± 2 ND
 CO, ml min−1 21 ± 2 41 ± 5* 41 ± 4§ 0.001 29 ± 3 49 ± 5* 39 ± 5 0.02
 SV, μl 56 ± 4 101 ± 11* 95 ± 5§ 0.016 63 ± 7 108 ± 9* 87 ± 10 0.01
Left ventricle wall and lumen measures
 LVAWTd, mm 0.70 ± 0.07 0.91 ± 0.05* 0.85 ± 0.04 0.052 0.81 ± 0.05 0.82 ± 0.11 0.84 ± 0.05 ND
 LVIDd, mm 3.40 ± 0.14 3.52 ± 0.11 3.68 ± 0.14 ND 3.50 ± 0.05 3.79 ± 0.17 3.86 ± 0.19 ND
 LVPWTd, mm 0.69 ± 0.04 0.83 ± 0.04* 0.78 ± 0.04 0.026 0.75 ± 0.02 0.92 ± 0.09 0.83 ± 0.05 ND
 LVIDs, mm 2.00 ± 0.24 1.96 ± 0.08 2.23 ± 0.13 ND 2.13 ± 0.12 2.28 ± 0.17 2.27 ± 0.11 ND
 RWT 0.41 ± 0.03 0.49 ± 0.03 0.45 ± 0.03 ND 0.45 ± 0.02 0.48 ± 0.08 0.43 ± 0.03 ND
 LVM, mg 59 ± 3 86 ± 4* 81 ± 3§ 0.001 76 ± 3 97 ± 7 98 ± 9 0.073
 LVM/TL, mg mm−1 4.30 ± 0.17 5.56 ± 0.36 5.71 ± 0.52 0.057
Page 8 of 15Habibi et al. Cardiovasc Diabetol  (2017) 16:9 
SGK1 upregulates ion channels, including ENaC, and is 
likewise a potent inducer of the SGLT1, a novel cardiac 
glucose transporter in type 2 diabetes [40]. Myocardial 
ENaC protein level (Fig. 6a), assessed by immunoblotting, 
was significantly elevated in DbC, compared to both CkC 
and DbE. We examined the expression of the α-subunit 
of the ENaC, as well as SGK1 in the LV using immunoflu-






























Fig. 3 Echocardiographic assessment of diastolic function. Cardiac function was evaluated in 11 week old mice prior to treatment (Pre) and again 
at 15 weeks of age at the end of treatment. Bar graphs show significant improvements in diastolic parameters in DbE compared to DbC including 
the a Tissue Doppler derived E′/A′ ratio indicating improved septal wall motion and b E/E′ ratio indicating improved LV filling pressure. *P < 0.05 
compared to CKC at the same time point; †P < 0.05 compared to DbC at the same time point
Fig. 4 Myocardial remodeling, but not oxidative stress is improved with empagliflozin. a WGA staining for determination of myocyte cross sectional 
area (CSA), magnification ×40, b Picrosirius red staining for determination of interstitial fibrosis. Magnification ×5, inset ×40 and c 3‑nitrotyrosine 
immunostaining for determination of oxidative stress. Magnification ×40, inset ×40. *P < 0.05 vs CkC and †P < 0.05 vs DbC. AGSI average grey scale 
intensities. All scale bars 50 μm
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myocardial expression of both ENaC and SGK1 in DbC 
compared to CkC, and normalization of these protein 
levels in DbE (Fig.  6b,c). In addition, myocardial ENaC 
protein level, assessed by immunoblotting, was signifi-
cantly elevated in DbC, compared to both CkC and DbE. 
We further examined signaling pathways for hypertro-
phy comprising Akt and ERK activation. Although the 
changes in phospho Akt ser473 and Thr308 were not 
statistically different between the three groups, the ratio 
of phospho Akt to total Akt was moderately increased 
(P  <  0.055 for ser473 and P  <  0.079 for thr308) due to 
significant decrease in total Akt in DbC and DbE groups 
compared to CkC (Additional file  1: Figure S2). Activa-
tion of ERK1/2 is another signaling pathway implicated 
in cardiac hypertrophy, but this pathway was not affected 
either in DbC and DbE (Additional file 1: Figure S2).
Myocardial ultrastructure
Compared to CkC, DbC exhibited  a marked expansion 
of inter myofibrillar mitochondria (IMF Mt) resulting in 
a disorganized appearance of sarcomeres (Fig.  7). Addi-
tionally, mitochondria displayed attenuation of matrix 
electron density, loss of cristae, fusion of cristae and 
mitochondrial fragmentation and these ultrastructural 
anomalies were improved by EMPA treatment.
Discussion
Collectively, the results of this investigation support 
the hypothesis that treatment with the SGLT2i, EMPA, 
improves cardiac diastolic function in female mice in the 
setting of obesity and diabetes, even in the absence of a 
reduction in BP. The improvement in diastolic function 
was associated, not only with improved glycemia, but 
with improvements in cardiac structure, including reduc-
tions in interstitial myocardial fibrosis and associated 
pro-fibrotic SGK1/ENaC protein expression levels, cardi-
omyocyte hypertrophy and cardiomyocyte mitochondrial 
ultrastructure. Although EMPA is reported to reduce BP 
in diabetic humans [41], we did not observe lower BP 
in treated mice, nor did we see an improvement in BP 
dipping status compared to diabetic mice not receiving 
EMPA. Thus, functional and structural improvements in 
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Fig. 5 Five weeks of empagliflozin treatment reduces the profibrotic protein expression levels of a, b ENaC and c SGK1. AGSI average grey scale 
intensities, AU arbitrary units *P < 0.05 vs CkC; †P < 0.05 vs DbC. Scale bars 50 μm
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Administration of SGLT2 inhibitors is reported to 
improve glycemia and promote weight loss and body fat 
mass reduction in humans and rodents with diabetes, in 
part, due to caloric loss associated with increased uri-
nary glucose excretion and a metabolic shift from carbo-
hydrate to fatty acid oxidation [42, 43]. In this regard, a 
4 week course of EMPA led to a slight reduction in tri-
glycerides in patients with type 2 diabetes [44]. By the 
end of this study, we observed that DbC mice exhibited 
moderate glycosuria indicated by the 54-fold increase 
in urinary glucose excretion compared to CkC. Impor-
tantly, at the end of the study period, EMPA-treated db/
db mice (10 mg kg−1 day−1) exhibited twice the urine glu-
cose excretion of untreated db/db mice, thus validating 
long-term SGLT2 inhibition. Pharmacologic inhibition of 
SGLT2 has been reported to induce increases in plasma 
insulin concentration in db/db mice [45] and Zucker dia-
betic fatty rats [46] in association with preservation of 
β-cell insulin secretion and consequent improved glyce-
mia. Consistent with those previous animal studies, we 
observed increased plasma insulin concentration. Our 
results demonstrate that the low dose of EMPA used in 
this study blunted the progression of hyperglycemia by 
inducing glycosuria. Improved glycemia is associated 
with preservation of β-cell function [47, 48]. Thus, the 
higher concentration of plasma insulin we observed with 
EMPA administration reflects therapeutic preservation 
of β-cell function and a slower decline in plasma insulin 
concentration. We did not observe differences in body 
weight or composition (lean or fat mass) or plasma or 
liver triglycerides between DbC and DbE. Similarly, treat-
ment of female db/db mice for 8 weeks of EMPA at the 
same dose as that used herein in our study had no effect 
on body weight [13].
In this study we have explored the mechanisms 
underlying diastolic dysfunction in female db/db mice, 
including myocardial fibrosis, hypertrophy and calcium 
handling. A major determinant of impairment of the 
passive properties of diastolic relaxation is cardiac fibro-
sis. In the setting of obesity and diabetes, an increase in 
myocardial interstitial fibrosis can occur in response to 
increased pressure or volume loading conditions and 
this is thought to impair normal rapid ventricular relaxa-
tion. Female diabetic db/db mice exhibit increased car-
diac interstitial fibrosis as early as 8 weeks of age [49] and 
we observed increased fibrosis in 16  week old females 
CkC DbC DbE 






































* †CkC DbC DbE a
b
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Fig. 6 Empagliflozin reduces myocardial profibrotic signaling. Five weeks of empagliflozin treatment reduces the profibrotic proein expression 
levels of a, b ENaC and c SGK1. AGSI average grey scale intensities, AU arbitrary units *P < 0.05 vs CkC; P < 0.05 vs DbC. Scale bars 50 µm
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(Fig.  4b). Although such a pathological remodeling 
response reduces LV wall stress and may confer short-
term benefits, stiffening of the myocardium can lead to 
reduced myocardial wall velocity during early diastole 
and more reliance on atrial contraction to complete fill-
ing of the LV in late diastole. Impairment in ventricular 
wall relaxation can be evaluated during routine echocar-
diography using Tissue Doppler Imaging (TDI) which 
allows for determination of the peak velocities of the 
myocardial wall during early (E′) and late diastole (A′). 
Indeed, our TDI examination revealed a reduction in 
the E′/A′ ratio in DbC mice before treatment began and 
at the end of the study suggesting chronic impaired LV 
wall relaxation early in diastole and enhanced late filling. 
Although at baseline this impairment existed in the DbE 
group by the end of treatment period this impairment 
was resolved. Perhaps most importantly, were the dif-
ferences in LV filling pressure or the E to E′ ratio, among 
groups of mice. Unlike some diastolic parameters, such 
as the E/A ratio, E/E′ is a load-independent parameter. 
DbC exhibited increased LV filling pressure at baseline, 
as well as at the end of the study period, whereas, DbE 
mice had elevated LV filling pressure at baseline and this 
impairment was normalized by the end of the study. The 
decrease in LV filling pressure and reduction in intersti-
tial fibrosis are consistent with an improvement in dias-
tolic function with EMPA treatment. Our findings of 
impairments in TDI derived diastolic function param-
eters are also consistent with a recent preliminary analy-
sis from the EMPA-REG OUTCOME trial [50]. In that 
study baseline echocardiography was performed on dia-
betes patients followed by treatment with 10  mg  day−1 
EMPA for 3  months and follow up echocardiography. 
EMPA resulted in an increase in E′ and a decrease in the 
LV mass index. These interesting findings suggesting that 
EMPA improves diastolic function will likely be explored 
more extensively in ongoing clinical trials.
Like cardiac fibrosis, left ventricular hypertrophy, a fre-
quent correlate of diastolic dysfunction [51], occurs in 
response to increased pressure or volume loading con-
ditions common in the setting of obesity and diabetes. 
We observed that standard hypertrophic parameters, 
IMF Mt
IMF Mt

















a CkC b DbC c DbE
d CkC e DbC f DbE
Fig. 7 Mitochondrial expansion and sarcomere disorganization in DbC is improved by empagliflozin treatment. a Illustrates the normal appearance 
of the inter myofibrillar (IMF) mitochondria (Mt) in the myocardium of CkC. Note the orderly row of sarcomeres (S) alternating with a row of IMF‑
Mt. Inset a shows normal cristae structure. b Depicts the marked IMF‑Mt expansion with attenuation of the Mt matrix electron density, loss of Mt 
cristae (inset b), fusion of Mt cristae and Mt fragmentation in the diabetic DbC models. Also note the disorganized appearance of the sarcomeres. 
c Demonstrates that empagliflozin protects the cardiomyocyte from IMF‑Mt expansion, decreased IMF‑Mt matrix electron density, IMF‑Mt cristae 
fragmentation (inset c), fusion of cristae and loss and sarcomere disorganization. Magnification ×2000; bar 1 µm in a–c. Insets a–c depict Mt cristae 
structure. Magnification ×4000; bar 0.5 µm. d–f represent CkC, DbC and DbE, respectively, at lower magnifications ×800; bar 2 µm
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including LV mass, LV mass adjusted for tibia length 
and cardiomyocyte cross sectional area, were increased 
or tended to be increased in both DbC and DbE com-
pared to CkC, and these results are consistent with a 
hypertrophic phenotype. Moreover, others have reported 
increased LV mass and wall thickness in female diabetic 
db/db mice of similar age and that remodeling was asso-
ciated with diastolic dysfunction [20]. In this study, rela-
tive wall thickness (RWT) did not differ among the three 
groups of mice. Prior to the start of treatment, anterior 
(LVAWTd) and posterior wall (LVPWTd) thicknesses 
at end diastole were moderately increased in DbC com-
pared to CkC (P < 0.5). Wall thickness were not different 
between DbC and DbE and they tended to be increased 
in DbE compared to CkC (P > 0.05). Moreover, there were 
no differences in RWT between the groups at the end of 
the study. Therefore, the increase in LV mass, in concert 
with no change in RWT, suggests that the LV of DbC 
exhibited eccentric, rather than concentric, hypertrophy. 
We speculate that cardiomyocytes may be lengthening in 
response to volume overload associated with profound 
obesity, as evidenced by the increase in CO in DbC. 
Nonetheless, DbC cardiomyocytes were more hypertro-
phied than those of DbE and CkC and this may be the 
result of stress on the LV wall caused by an increase in LV 
filling pressure. DbE showed lesser cardiomyocyte hyper-
trophy likely in response to a reduction in LV filling pres-
sure and the decrease in cardiomyocyte hypertrophy was 
only a partial effect compared to the normalizing effect of 
EMPA on interstitial fibrosis. This suggests cardiac fibro-
sis contributes mainly to diastolic dysfunction.
We explored several pathways that contribute to cardiac 
remodeling and diastolic dysfunction, some of which have 
not been examined in previous studies. Emerging evi-
dence supports a role for SGK1 and ENaC in promoting 
fibrosis and adverse hypertrophy in human and murine 
heart disease [7, 8]. SGK1 is highly expressed in human 
and murine hearts and is upregulated in pathophysiologi-
cal settings, including obesity, heart disease and diabetes 
[40]. SGK1 regulates the expression of a number of ion 
channels, including ENaC [7, 9] which is upregulated in 
tissues in the setting of obesity and diabetes [52]. Indeed, 
SGK1 is rapidly activated and induces adverse ventricu-
lar remodeling, including, fibrosis, an increase in cardio-
myocyte cell size and LV hypertrophy in a murine model 
of transthoracic aortic constriction [7, 8]. On the other 
hand, SGK1 may protect cardiomyocytes from apoptosis 
[8]. Little is known about the role of SGK1 and ENaC in 
the diabetic db/db heart or the impact of EMPA on myo-
cardial ENaC and SGK1 expression/activation. To our 
knowledge, this is the first study to examine the expres-
sion of SGK1 and the α-subunit of the epithelial sodium 
channel, ENaC, in the parenchyma and vasculature of 
the LV. In this study, we observed increases in myocar-
dial expression of SGK1 and ENaC and normalization of 
these protein levels by EMPA. These results suggest that 
the improvement in cardiac function may be modulated, 
in part, through improvement in SGK1/ENaC activity in 
the heart. The changes in expression of these proteins may 
be due to significant improvement in hyperglycemia since 
high glucose has been shown to increase the expression 
of SGK1 and ENaC in distal renal tubular cells in  vitro 
[53]. However, the effects of high glucose on SGK1 and 
ENaC in cardiomyocytes or coronary endothelial cells of 
db/db mice has not been examined. We also examined 
the potential contribution of the pro-hypertrophic signal-
ing pathways, Akt and ERK (Additional file 1: Figure S2). 
Although compared to CkC, Akt tended to be activated 
in both DbC and DbE, there was no difference in the acti-
vation state between DbC and DbE. The activation state 
of ERK did not differ among groups of mice. Thus, the 
modest improvement in hypertrophy in DbE is not likely 
mediated by effects of EMPA on Akt or ERK. The absence 
of evidence for contributions from Akt and ERK to car-
diac remodeling in female db/db mice examined in this 
study highlight the potential contributions of SGK1 and 
eNAC to cardiac fibrosis and hypertrophy.
In this study, changes in sarco/endoplasmic reticulum 
Ca2+-ATPase (SERCA), SERCA to phospholamban (PLB) 
ratio and phosphorylation of PLB may potentially affect 
diastolic function [54]. Although others have reported 
altered gene expression of SERCA2A and PLB in 18 week 
old female db/db mice, we observed no differences 
among groups in protein expression (not shown) and 
thus cannot ascribe the differences in diastolic function 
observed among these proteins. Thus, we conclude these 
pathways do not explain the improvements in cardiac 
function observed. On the other hand, we did observe 
improved cardiomyocyte mitochondrial ultrastructure 
and sarcomere organization that may, in part, contribute 
to improved diastolic function as we have observed in 
this and other rodent models of cardiac dysfunction and 
obesity [29, 31, 32, 55].
Signaling through RAGE has been implicated in 
numerous disease conditions, including diabetes and 
heart disease. RAGE can bind multiple ligand types, 
including, but not limited to a heterogenous group of 
advanced glycation end products (AGEs). AGEs accu-
mulate as a consequence of long-term hyperglycemia 
and contribute to the pathogenesis of diabetic cardiomy-
opathy [56]. AGE accumulation can lead to generation 
of reactive oxygen species (ROS) and upregulation of 
RAGE. Moreover, AGEs have been shown to induce the 
expression of ENaC via activation of SGK1 [57]. Recent 
evidence in mice suggests there is RAGE upregulation 
in cardiomyocytes that contributes to cardiomyopathy 
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[58]. Herein, we show that myocardial AGE expression 
is increased in DbC and DbE, compared to CkC, and 
observe that it is widely distributed throughout the LV 
wall, including in the vasculature. This occurred in con-
cert with increased RAGE expression. In the DbC, the 
increases in both AGE and RAGE were associated with 
an increase in oxidative stress. Nonetheless, despite the 
modest improvement in HbA1c in DbE, EMPA did not 
reduce AGE accumulation in the heart. In this regard, 
a recent study utilizing a rodent model of type 1 (strep-
tozotocin model) diabetes, reported that a low dose of 
EMPA (10  mg  kg−1  day−1), the same dose used in this 
study, was not associated with suppression of AGE, 
RAGE or ROS formation in aortic tissue or serum meth-
ylglyoxal, an AGE precursor, although treatment did 
improve aortic remodeling and reactivity to acetylcho-
line [16]. In that study, a threefold higher dose of EMPA 
did reduce AGE and RAGE expression, as well as ROS 
formation in the aortic wall. It should be noted that the 
glycation process in vivo results in formation of early gly-
cation products, such as HbA1c and glycated albumin, 
whereas advanced glycation products require longer 
times to accumulate relative to early glycation products. 
In this regard, a previous study reported that advanced 
glycated Hb (Hb-AGE) was significantly increased with 
high level of HbA1c in diabetic patients, but Hb-AGE 
did not correlate with diabetes duration and correlated 
poorly in a well-controlled sub-group [59].
Evidence from a recent clinical trial (EMPA-REG BP™) 
examining the effects of a 12  week course of EMPA on 
male and female patients with type 2 diabetes and hyper-
tension demonstrates improvements in both sexes in SBP 
and DBP (~3.9 and 1.5 mmHg, respectively compared to 
placebo), as well as indirect markers of arterial stiffness 
and vascular resistance [41, 60]. In the untreated db/db 
mice examined here (DbC), we observed increased SBP 
and DBP, as well as impaired BP dipping, all of which 
were unaffected by EMPA. It is possible that the 5 week 
duration of our study was too brief to induce a detectable 
decrease in BP.
Coinciding with the preparation of this manuscript 
there was a more recent report from the EMPA-REG 
outcome trial demonstrating improvement in Tissue 
Doppler derived diastolic function in diabetes patients 
administered EMPA [50]. That EMPA resulted in similar 
improvement in myocardial wall relaxation in both dia-
betes patients and in diabetic db/db mice suggests that 
the present db/db model has potential clinical transla-
tional relevance.
The absence of data on the effects of EMPA on myo-
cardial metabolism and insulin sensitivity is a limita-
tion of this study. In this regard, a recent study reported 
increases in glucose disposal rate and liver, kidney and 
heart tissue glucose uptake, by euglycemic–hyperinsu-
linemic clamp, in female db/db mice treated with EMPA 
for 8  weeks at the same dose used in this study [13]. 
Thus it is possible that the improvement in diastolic dys-
function observed in this study could be due, in part, to 
increased myocardial glucose uptake and improvement 
in myocardial insulin sensitivity. Further study is needed 
to determine whether improvement in myocardial insulin 
sensitivity contributes to improved diastolic function in 
db/db mice treated with EMPA.
In conclusion, data presented herein support a newly 
described pleiotropic protective affect of EMPA on dias-
tolic function and cardiac structure in the diabetic db/
db mouse with established impaired diastolic relaxa-
tion, albuminuria and elevated BP. Specifically, we 
observed improvement in diastolic function, myocar-
dial fibrosis, cardiomyocyte hypertrophy and ultras-
tructure of inter myofibrillar mitochondria that were 
associated with a significant improvement in glycemia, 
as well as improvement in myocardial expression of 
SGK1 and ENaC. Despite the improvement in glycemic 
control, HbA1c and fasting glucose were still elevated 
above normoglycemia values. Moreover, we did not see 
any marked improvements in body composition, lipid 
(plasma or liver triglycerides) or BP control or BP dip-
ping, or reductions in myocardial accumulation of AGE/
RAGE and protein nitrosylation with 5 weeks of EMPA 
treatment. It was recently highlighted that the unex-
plained aspects of the EMPA-REG OUTCOME results 
are that the cardiovascular and kidney benefits of EMPA 
occurred without dramatic improvements in glycemic, 
lipid, or BP control [61]. Therefore, it is possible that the 
pleiotropic effects of EMPA relate to factors other than 
improvements in glycemia and lipidemia. In this regard, 
the effect of EMPA on metabolic remodeling in tissues 
is emerging [61, 62]. Additional studies are needed to 
further elucidate the potential role for myocardial SGK1 
and ENaC as mediators of the efficacy of EMPA. The 
findings of this investigation in a preclinical model sug-
gest a potential clinical utility for EMPA in the treatment 
of diastolic dysfunction given the high incidence of dias-
tolic dysfunction and the cardiovascular risks associated 
with this abnormality in the diabetic population and in 
women in particular.
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